The authors speculated that SIK inhibition could be a therapeutic paradigm for CKD, based on their observation that SIK inhibition increased 1,25-vitamin D levels in mice with CKD despite increased systemic FGF23 levels. The gene discussed is FGF23; the disease is chronic kidney disease.